This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Daniel Temianka, MD
Los Angeles, Calif

JAMA. 1994;272(24):1896-1897.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—That the principal investigators in the two recent studies^1,2 of tacrine are employees of and hold stock options in Parke-Davis Pharmaceutical Research Division of Warner-Lambert Co represents a glaring and hopeless conflict of interest. I believe that this accounts for the overall favorable tone of the articles' conclusions, despite the overwhelming evidence that tacrine is a grossly hepatotoxic drug with unpleasant side effects.

I am grateful that JAMA's editorial policy requires disclosure of such financial interests, but it is disturbing that the accompanying Editorial ignored them. I believe that these articles should not have been printed in a peer-reviewed journal. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?